Acorda Therapeutics 대차 대조표 상태

재무 상태 기준 확인 0/6

Acorda Therapeutics 의 총 주주 지분은 $-185.8M 이고 총 부채는 $191.5M, 이는 부채 대 자기자본 비율을 -103.1% 로 가져옵니다. 총자산과 총부채는 각각 $81.6M 및 $267.3M 입니다.

주요 정보

-103.1%

부채 비율

US$191.47m

부채

이자 보상 비율	n/a
현금	US$9.36m
주식	-US$185.77m
총 부채	US$267.35m
총 자산	US$81.58m

최근 재무 상태 업데이트

Recent updates

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Feb 21

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Dec 18

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Jun 05

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Oct 17

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Oct 10

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action

Jun 17

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

May 26

Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Mar 09

재무 상태 분석

단기부채: ACOR.Q 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

장기 부채: ACOR.Q 의 주주 지분은 음수입니다. 이는 장기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

부채 대 자본 내역 및 분석

부채 수준: ACOR.Q 은 부정주주자본을 갖고 있는데, 이는 높은 부채 수준보다 더 심각한 상황입니다.

부채 감소: ACOR.Q 의 주주 지분은 음수이므로 시간이 지남에 따라 부채가 감소했는지 확인할 필요가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: ACOR.Q 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 14.5 %의 역사적 비율로 계속 감소할 경우 ACOR.Q 의 현금 활주로는 1년 미만입니다.

Acorda Therapeutics 대차 대조표 상태

재무 상태 기준 확인 0/6

주요 정보

최근 재무 상태 업데이트

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Motion for Asset Sale Filed by Acorda Therapeutics, Inc.

Recent updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite Index

Motion for Asset Sale Filed by Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.

Acorda Therapeutics, Inc. Filed for Bankruptcy

Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

New minor risk - Share price stability

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Third quarter 2023 earnings released: US$7.16 loss per share (vs US$11.41 loss in 3Q 2022)

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA

New minor risk - Shareholder dilution

Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$7.55 loss per share (vs US$55.63 loss in 2Q 2022)

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select Market

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing

First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)

Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A Hearing

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027

Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Acorda inks license deal with Asieris for pre-clinical drug

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Acorda Therapeutics announces resignation of COO

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)

Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock Market

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)

Acorda Therapeutics: Managing The Transition

Independent Director Barry Greene has left the company

Independent Director Catherine D. Strader has left the company

Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)

Acorda Therapeutics Continues To Maneuver For A Turnaround

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)

Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021

Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

Analysts increase revenue estimates to US$95.7m

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)

Revenue and earnings beat expectations

Acorda Therapeutics Announces Executive Changes

Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR).

Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

Price target lowered to US$19.50

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic Index

New 90-day high: US$6.70